RNAi Message Board - Msg: 22862101

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	9/29/2006 2:30:58 PM
	of 671

9:01AM AVI BioPharma presents positive preclinical data evaluating Neugene antisense compounds against influenza A Virus and the E. coli bacteria (AVII) 3.52 : Co announces it presented preclinical data regarding the use of its Neugene antisense technology against influenza A and E. coli infection. The data was presented in two posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy meetings. The first presentation, titled "Inhibition of Several Subtypes of Influenza A Virus with Antisense Morpholino Oligomers" presented data that showed that two AVI antisense compounds inhibited several strains of influenza A, including the avian strain H5N1 in cell culture as previously reported. Experiments in mice are ongoing. The second presentation, titled "Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugate: Dose-Response in Mice Infected with Escherichia Coli," data showed that the AVI antisense compounds promoted survival in mice infected with E. coli. These antisense compounds, referred to as NeuBiotics, reduced bacteremia in mice by three orders of magnitude compared with controls.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next